We are live on ! Find out more

Invesco Biotechnology & Genome ETF

PBE

Market cap $445M

102.50 USD

-0.96

0.93%

At close Updated Oct 30, 4:00 PM EDT

1 day

-0.93%

5 days

3.51%

1 month

5.36%

3 months

12.51%

6 months

28.8%

Year to date

24.47%

1 year

39.99%

5 years

33.71%

10 years

174.28%

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 22.2%

Neutral 66.7%

Negative 11.1%

Zacks Investment Research

Why Healthcare ETFs Are Hovering Around One-Year Highs

Healthcare ETFs are hovering near 52-week highs as earnings prospects improve, clinical breakthroughs advance and GLP-1 demand expands. Explore five ETFs riding the rally.

Why Healthcare ETFs Are Hovering Around One-Year Highs

Zacks Investment Research

Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?

The Invesco Biotechnology & Genome ETF (PBE) made its debut on 06/23/2005, and is a smart beta exchange traded fund that provides broad exposure to the Health Care ETFs category of the market.

Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?

Zacks Investment Research

Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)?

Launched on June 23, 2005, the Invesco Biotechnology & Genome ETF (PBE) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Biotech segment of the equity market.

Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)?

The Motley Fool

PBE vs. RSPH: Is a Biotech ETF or Equal-Weight Healthcare ETF the Better Choice for Investors?

PBE offers a higher dividend yield and has delivered stronger one-year total returns. RSPH offers a more affordable expense ratio and a significantly lower historical drawdown.

PBE vs. RSPH: Is a Biotech ETF or Equal-Weight Healthcare ETF the Better Choice for Investors?

The Motley Fool

iShares' IYH or Invesco's PBE: Which Healthcare ETF Is the Better Long-Term Buy?

iShares U.S. Healthcare ETF offers a more diversified portfolio and lower expense ratio than Invesco Biotechnology & Genome ETF. Invesco Biotechnology & Genome ETF delivered a higher 1-year total return but has experienced significantly larger historical drawdowns.

iShares' IYH or Invesco's PBE: Which Healthcare ETF Is the Better Long-Term Buy?

Zacks Investment Research

Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?

Designed to provide broad exposure to the Health Care ETFs category of the market, the Invesco Biotechnology & Genome ETF (PBE) is a smart beta exchange traded fund launched on 06/23/2005.

Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?

The Motley Fool

VanEck Pharmaceutical ETF vs. Invesco Biotech ETF: Which Fund Fits Your Investing Style?

VanEck Pharmaceutical ETF features a lower expense ratio of 0.36% compared to 0.58% for Invesco Biotechnology & Genome ETF. Invesco Biotechnology & Genome ETF delivered a higher 1-year total return of 47.3% but experienced a significantly deeper maximum drawdown of 34.7%.

VanEck Pharmaceutical ETF vs. Invesco Biotech ETF: Which Fund Fits Your Investing Style?

Zacks Investment Research

Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)?

Launched on June 23, 2005, the Invesco Biotechnology & Genome ETF (PBE) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Biotech segment of the equity market.

Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)?

The Motley Fool

XLV vs PBE: Is a Low-Cost Healthcare ETF the Better Buy Than a Focused Biotech Specialist?

State Street Health Care Select Sector SPDR ETF offers a significantly lower expense ratio of 0.08% compared to 0.58% for Invesco Biotechnology & Genome ETF Invesco Biotechnology & Genome ETF holds a concentrated basket of 30 biotech firms, whereas State Street Health Care Select Sector SPDR ETF provides exposure to 60 broad healthcare companies State Street Health Care Select Sector SPDR ETF has experienced a shallower maximum drawdown and lower volatility than Invesco Biotechnology & Genome ETF over the last five years

XLV vs PBE: Is a Low-Cost Healthcare ETF the Better Buy Than a Focused Biotech Specialist?

The Motley Fool

VHT vs. PBE: Which Health Care ETF Is the Better Buy?

The Vanguard Health Care ETF (VHT) offers broader health care exposure and has a a lower expense ratio than the Invesco Biotechnology & Genome ETF (PBE). PBE has delivered a stronger 1-year return, but has also experienced a much steeper 5-year maximum drawdown.

VHT vs. PBE: Which Health Care ETF Is the Better Buy?

See News Rankings

Price charts implemented using Lightweight Charts™